Biogen shares plunge Thursday, wiping nearly $20 billion in value from the biotech group, after it dropped a late-stage trial for a key Alzheimer's disease drug.

Stocks recoup some losses in late trading but close lower as momentum from a report that China and the U.S. are in the final stages of completing a trade deal fades.

Biogen will purchase Nightstar Therapeutics in an all-cash deal that values the British gene-therapy company at $877 million.

Amgen is upgraded from hold to buy by Citigroup.

These stocks, including News Corp. and Royal Bank of Scotland, could be staging a technical move.

This is very different than the Big Mac you know and love.

The billionaire and crypto investor was in business with Voyager Digital which went bankrupt early July.

The builder confidence index breached the break-even measure of 50 in August for the first time since May 2020.

China is a crucial country for Tesla for its domination of the market of electric vehicles.